Thomas Smith
Stock Analyst at Leerink Partners
(1.07)
# 3,632
Out of 4,862 analysts
67
Total ratings
29.51%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.34 | +194.12% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.67 | +438.92% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.48 | +374.58% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $3.14 | +823.57% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $10.37 | +276.08% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $8.27 | +214.39% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $1.05 | +856.94% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $6.97 | +186.94% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $577.05 | -24.62% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $53.72 | -32.99% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $0.95 | +636.84% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $15.64 | +34.31% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $15.89 | +183.20% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $6.09 | -1.40% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $3.71 | +61.94% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.80 | +521.20% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $44.16 | -61.50% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $21.22 | +201.60% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $19.50 | +258.97% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $10.40 | +178.85% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.88 | +802.78% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $26.08 | -53.99% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $4.14 | +141.54% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $3.35 | +11,840.30% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $13.56 | +490.19% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.34
Upside: +194.12%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.67
Upside: +438.92%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.48
Upside: +374.58%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $3.14
Upside: +823.57%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $10.37
Upside: +276.08%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $8.27
Upside: +214.39%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $1.05
Upside: +856.94%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $6.97
Upside: +186.94%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $577.05
Upside: -24.62%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $53.72
Upside: -32.99%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $0.95
Upside: +636.84%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $15.64
Upside: +34.31%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $15.89
Upside: +183.20%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $6.09
Upside: -1.40%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $3.71
Upside: +61.94%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.80
Upside: +521.20%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $44.16
Upside: -61.50%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $21.22
Upside: +201.60%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $19.50
Upside: +258.97%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $10.40
Upside: +178.85%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.88
Upside: +802.78%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $26.08
Upside: -53.99%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $4.14
Upside: +141.54%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $3.35
Upside: +11,840.30%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $13.56
Upside: +490.19%